Autolus Therapeutics plc Cash And Cash Equivalents At Carrying Value

• Autolus Therapeutics plc showed a decrease of -54.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Autolus Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
• XBRL data for this metric is available from 2021 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2021 to 2025), Autolus Therapeutics plc's Cash And Cash Equivalents At Carrying Value has declined by 66.4%.
• Historical annual values: Fiscal year 2025: $104.13 million | Fiscal year 2024: $227.38 million | Fiscal year 2023: $239.57 million | Fiscal year 2023: $256.42 million | Fiscal year 2023: $307.50 million | Fiscal year 2023: $343.03 million | Fiscal year 2022: $382.44 million | Fiscal year 2022: $163.05 million | Fiscal year 2022: $216.44 million | Fiscal year 2022: $268.56 million | Fiscal year 2021: $310.34 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026